HIV trials in Africa: Difference between revisions

Refutation: Add text and citations.
Add text and citation.
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
In 2005 and 2007, randomized controlled trials (RCTs) were carried out in Africa in an attempt to prove a hypothesis of certain [[circumcision advocate|circumcision promoters]] despite the known [[Immunological and protective function of the foreskin| immunological functions]] of the [[foreskin]], to link HIV infection to lack of [[circumcision]].
In 2005 and 2007, randomized controlled trials (RCTs) were carried out in Africa in an attempt to prove a hypothesis of certain [[circumcision advocate|circumcision promoters]] despite the known [[Immunological and protective function of the foreskin| immunological functions]] of the [[foreskin]], to link [[HIV]] infection to lack of [[circumcision]].


These trials were carried out in
These trials were carried out in
* South Africa:
* [[South Africa]]:
: {{RCT Auvert et al 2005}}
: {{RCT Auvert et al 2005}}
* Kenya:
* Kenya:
Line 10: Line 10:


The 2007 RCTs in Kenya and Uganda were funded by NIAID director [[Anthony Fauci]].
The 2007 RCTs in Kenya and Uganda were funded by NIAID director [[Anthony Fauci]].
[[PEPFAR]] (2025) has scrapped its ineffective and harmful "voluntary male  medical circumcision" (VMMC) program after 15 years and at least 27,000,000 harmful and useless [[foreskin]] amputations.<ref name="gwarisa2025">{{REFnews
|title=New PEPFAR Waiver Scraps Voluntary Medical Male Circumcision Program
|url=https://healthtimes.co.zw/2025/02/07/new-pepfar-waiver-scraps-voluntary-medical-male-circumcision-program/
|last=Gwarisa
|first=Michael
|init=
|author-link=
|publisher=Healthtimes
|website=
|date=2025-02-07
|accessdate=2025-02-16
|format=
|quote=
}}</ref> The [[United States]] government will no longer pay for harmful circumcisions in Africa.


== 60% HIV protection myth ==
== 60% HIV protection myth ==
Line 70: Line 85:
  |last=Mayan
  |last=Mayan
  |first=Madhur
  |first=Madhur
  |init=
  |init=M
  |author-link=
  |author-link=
  |last2=Hamilton
  |last2=Hamilton
  |first2=Robert J.
  |first2=Robert J.
  |init2=
  |init2=RJ
  |author2-link=
  |author2-link=
  |last3=Juurlink
  |last3=Juurlink
  |first3=David N.
  |first3=David N.
  |init3=
  |init3=DN
  |author3-link=
  |author3-link=
  |last4=Austin
  |last4=Austin
  |first4=Peter C.
  |first4=Peter C.
  |init4=
  |init4=PC
  |author4-link=
  |author4-link=
  |last5=Jarvi
  |last5=Jarvi
  |first5=Keith A.
  |first5=Keith A.
  |init5=
  |init5=KA
  |author5-link=
  |author5-link=
  |etal=no
  |etal=no
  |title=Circumcision and Risk of HIV Among Males From Ontario, Canada
  |title=Circumcision and Risk of HIV Among Males From Ontario, Canada
|trans-title=
|language=
  |journal=J Urol
  |journal=J Urol
|location=
  |date=2021-09-23
  |date=2021-09-23
  |volume=
  |volume=
Line 101: Line 113:
  |pages=
  |pages=
  |url=https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000002234
  |url=https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000002234
|archived=
  |quote=We found that circumcision was not independently associated with the risk of acquiring HIV among men from Ontario, Canada.
  |quote=We found that circumcision was not independently associated with the risk of acquiring HIV among men from Ontario, Canada.
  |pubmedID=34551593
  |pubmedID=34551593
Line 107: Line 118:
  |DOI=10.1097/JU.0000000000002234
  |DOI=10.1097/JU.0000000000002234
  |accessdate=2022-01-07
  |accessdate=2022-01-07
}}</ref> <ref name="frisch2021">{{REFjournal
}}</ref><ref name="frisch2021">{{FrischM SimonsenJ 2021}}</ref>
|last=Frisch
{{SEEALSO}}
|first=Morten
* [[HIV]]
|init=
* [[South Africa]]
|author-link=Morten Frisch
|last2=Simonsen
|first2=Jacob
|init2=
|author2-link=
|etal=no
|title=Non-therapeutic male circumcision in infancy or childhood and risk of human immunodeficiency virus and other sexually transmitted infections: national cohort study in Denmark
|trans-title=
|language=
|journal=Eur J Epidemiol
|location=
|date=2021-09-26
|volume=Published online ahead of print
|issue=
|article=
|page=
|pages=
|url=https://link.springer.com/article/10.1007/s10654-021-00809-6
|archived=
|quote=
|pubmedID=34564796
|pubmedCID=
|DOI=10.1007/s10654-021-00809-6
|accessdate=2022-01-07
}}</ref>
 
{{REF}}
{{REF}}


Line 146: Line 131:
[[Category:South Africa]]
[[Category:South Africa]]
[[Category:Uganda]]
[[Category:Uganda]]
[[de:HIV-Studien in Afrika]]